These participants were categorized as having significant AD pathologic change (n = 59) or not (n = 46) based on the Alzheimer's disease neuropathologic change (ADNC) scale, in which both amyloid and tau pathologies are accounted for (Montine et al, 2012). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.